Vaxcyte Inc
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrie… Read more
Vaxcyte Inc (PCVX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.084x
Based on the latest financial reports, Vaxcyte Inc (PCVX) has a cash flow conversion efficiency ratio of -0.084x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-224.83 Million) by net assets ($2.69 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Vaxcyte Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Vaxcyte Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Vaxcyte Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vaxcyte Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SINOPHARM GROUP 1/5/O.N.
F:X2S1
|
N/A |
|
Henry Schein Inc
NASDAQ:HSIC
|
0.036x |
|
Neles Oyj
HE:METSO_old
|
0.024x |
|
MTN Group Ltd PK
PINK:MTNOY
|
0.207x |
|
Xero Ltd
AU:XRO
|
0.132x |
|
Klépierre SA
PINK:KLPEF
|
0.039x |
|
YPF Sociedad Anonima
NYSE:YPF
|
0.000x |
|
Ryder System Inc
NYSE:R
|
-0.614x |
Annual Cash Flow Conversion Efficiency for Vaxcyte Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Vaxcyte Inc from 2017 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.69 Billion | $-655.58 Million | -0.244x | -78.29% |
| 2024-12-31 | $3.31 Billion | $-452.63 Million | -0.137x | +42.77% |
| 2023-12-31 | $1.24 Billion | $-296.79 Million | -0.239x | -33.74% |
| 2022-12-31 | $953.61 Million | $-170.60 Million | -0.179x | +58.14% |
| 2021-12-31 | $284.02 Million | $-121.39 Million | -0.427x | -217.02% |
| 2020-12-31 | $345.84 Million | $-46.63 Million | -0.135x | -130.42% |
| 2019-12-31 | $-106.37 Million | $-47.15 Million | 0.443x | -16.02% |
| 2018-12-31 | $-57.73 Million | $-30.47 Million | 0.528x | +109219.53% |
| 2017-12-31 | $30.94 Million | $-14.96K | 0.000x | -- |